Medscape

FDA Approves Human Fibrinogen Concentrate for Treatment of Bleeding in Congenital Fibrinogen Deficiency

January 28, 2009 — On January 16, the US Food and Drug Administration (FDA) granted accelerated approval to human fibrinogen concentrate (RiaSTAP, CSL Behring). This orphan drug is intended for use in ...
News Medical

Fibrinogen a key player in health and disease, says new study

A new study from the University of Alberta demonstrated that the blood clotting protein called fibrinogen also regulates MMP-2, an enzyme involved in immunity and in clot formation inside blood ...
Medscape

FDA Approves Novel Fibrinogen Concentrate for CFD

The fibrinogen concentrate is approved for children and adults with acute bleeding related to certain types of congenital ...
EurekAlert!

Understanding the impact of fibrinogen modifications on blood clot formation and degradation

The top panel, designed with BioRender.com, illustrates the process of clot formation and lysis, beginning with platelet aggregation and activation of the coagulation cascade, followed by the ...
The Pharma Letter

FDA approves Grifols’ Fesilty for rare bleeding disorder

Barcelona, Spain-based Grifols announced that its fibrinogen concentrate, Fesilty (fibrinogen, human-chmt), has been approved by the US Food and Drug Administration (FDA) for the treatment of acute ...
Pharm Exec

FDA Approves Expanded Indication for Octapharma’s Fibryga for Patients Experiencing Bleeding Due to Acquired Fibrinogen Deficiency

Expanded indication makes Fibryga the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication. The FDA has approved an expanded indication ...
WebMD

What to Know About Fibrin Degradation Products

Fibrin degradation products (FDPs) — also called fibrin split products — are small pieces of protein that stay in your blood when a blood clot dissolves inside your body. Doctors can test for the ...